BioMed Research International / 2017 / Article / Tab 1

Research Article

TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China

Table 1

Baseline of patients with CHB in NA-naïve and NA-experienced group, respectively.

TDF NA-naïveTDF NA-experiencedStatistics
()()

Age (years)35 (26–61)34.0 (24–61)0.128
Sex (male, %)72.2 (26/36)71.2 (47/66)0.914
Body mass index (kg/m2)22.63 ± 2.7323.85 ± 2.860.723
Follow-up time (weeks)42.0 (25.0–109.0)55.5 (24.0–110.0)0.199
The proportion of alcohol history (%)22.2 (8/36)25.8 (17/66)0.692
The proportion of smoking history (%)38.9 (14/36)21.2 (14/66)0.056
Family history of hepatitis B (%)58.3 (21/36)48.5 (32/66)0.341
ALT baseline (U/L)136.0 (56–597)80 (10–1231)0.786
HBV DNA baseline (log10 IU/ml)6.50 ± 0.695.78 ± 1.490.054
NA-experienced (%) previouslyN/ALMV (%)6.06 (4/66)
ADV (%)1.51 (1/66)
LdT (%)9.09 (6/66)
ETV (%)10.6 (7/66)
Complicated# (%)72.7 (48/66)
Rate of hepatitis B e antigen positive (%)50.0 (18/36)53.0 (35/66)0.770

ALT: alanine aminotransferase; TDF: tenofovir disoproxil fumarate; NA: nucleos(t)ide analogue. N/A: not applicable. LMV: lamivudine, LdT: telbivudine, ADV: adefovir dipivoxil, and ETV: entecavir.
#Complicated experience means at least two or more than two different NAs before switching to TDF.